Pancreatic Cancer Research

ResearcherUniversity of OxfordActive in the last 2 years

Paul Miller

ORCID-verified (high confidence, 0.95), identity_conf@1As of 8 November 2026

Matched on ORCID iD 0000-0002-5800-1220. Sources: OpenAlex.

Their work

Papers
2
Trials
0
Grants
0
Labs led
0
Collaborators
5
Papers, trials and grants by year

2023: 1 paper · 2024: none · 2025: 1 paper

Papers 2

  1. Impact of Long-Term Chemotherapy on Outcomes in Pancreatic Ductal Adenocarcinoma: A Real-World UK Multi-Centre Study. Co-author DOI 10.3390/cancers17111896↗
  2. p53 inhibitor iASPP is an unexpected suppressor of KRAS and inflammation-driven pancreatic cancer. Co-author DOI 10.1038/s41418-023-01168-3↗

Closest collaborators

The 5 strongest of 5 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Daniel Hochhauser · 1 shared paper, 2025 · strength 0.25
  2. Umair Mahmood · 1 shared paper, 2025 · strength 0.25
  3. Khurum Hayat Khan · 1 shared paper, 2025 · strength 0.25
  4. Xin Lü · 1 shared paper, 2023 · strength 0.17
  5. Eric E. O’Neill · 1 shared paper, 2023 · strength 0.17

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.